• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Melatonin for Insomnia in Patients With Autism

Melatonin for Insomnia in Patients With Autism

June 11, 2019
Jess Levy, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jess Levy, MD. Dr. Levy has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Maras A et al, J Child Adolesc Psychopharmacol 2018;28(10):699–710

Treating sleep problems in youth with autism spectrum disorder (ASD) is tricky at best. One promising treatment is pediatric prolonged-release melatonin ­(PedPRM) sold under the name Slenyto. In 2017, a randomized controlled trial (funded by the manufacturer) assigned 119 children with ASD and insomnia to either PedPRM (n = 58) or placebo (n = 61). PedPRM outperformed placebo: 68.9% of patients taking the medication had improved sleep outcomes vs only 39.3% of those assigned to placebo (p = .001).

Now a new article has been published to determine whether PedPRM maintains its effectiveness over the long term. A total of 95 patients entered this open-label phase, and 84% (n = 80) completed the phase. The average age of the patients was 9 years, and 75% were male. Youths previously randomized to placebo were switched to PedPRM and titrated to a maximum dose of 10 mg/day.

After 37 weeks, children originally randomized to and maintained on PedPRM showed sustained improvements: shorter sleep latency, greater length of sleep, fewer awakenings, and better sleep quality. In addition, those who previously received placebo showed improvement in sleep length and onset after switching to PedPRM. Caregivers’ quality of life improved as well, with 49% of caregivers experiencing an improvement on the quality-of-life scale used in the study.

The most common side effect of PedPRM was daytime fatigue, which occurred in 18% of the patients. There were no serious adverse events attributed to the medication, including aggression.

CCPR’s Take
This industry-funded study reports compelling results, which begs us to presume bias despite what appears to be sound methodology. It would be helpful to see a head-to-head study vs over-the-counter melatonin, which is cheaper albeit with less reliable pill-to-pill variability.

Still, PedPRM may be a viable treatment option for children with autism and insomnia who have failed a comprehensive sleep hygiene approach including attention to sensory issues, daily exercise, and psychotherapy, all of which might be effective in this population.
Child Psychiatry
KEYWORDS autism child_psychiatry research-update sleep_disorders
    Jess Levy, MD.

    Using an Interpreter in Psychiatric Practice

    More from this author
    www.thecarlatreport.com
    Issue Date: June 11, 2019
    SUBSCRIBE NOW
    Table Of Contents
    Note From the Editor-in-Chief
    Medications for Depression
    Practical Approaches to Vetting Clinical Research
    FDA Approves Adhansia XR
    First Non-Drug Treatment Approved by FDA for Treating Children With ADHD
    Prescribing Patterns for Children With Anxiety Disorders
    Melatonin for Insomnia in Patients With Autism
    Steroid-Induced Psychosis in the ­Pediatric Population
    Risk of Psychosis With Stimulants in ADHD Patients
    Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents
    CME Post-Test - Depression in Children and Adolescents, CCPR, Summer 2019
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.